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ABSTRACT 
 
CASSIDY BALDWIN: Technique for the Synthesis of Difluorinated Organic Molecules 
Using Magnesium Bases 
(Under the direction of David A. Colby) 
 
 
The presence of fluorine in organic molecules can confer biological advantages 
which are often exploited in drug development. For example, fluorine has been shown to 
limit drug metabolism and enhance drug distribution. However, the development of 
fluorinated pharmaceutics poses synthetic challenges. These challenges are especially 
pronounced when developing molecules with a difluoromethyl group. One difluoromethyl 
functional group of particular interest is the α,α-difluoro-β-amino carbonyl group, which 
has been seen in potential drug leads. The previous methods of accessing this group are 
inefficient and complex. The goal of this project was to develop a new technique to access 
this group by reacting α,α-difluoroenolate intermediates with unactivated imines in the 
presence of magnesium bases. The results showed evidence that a simpler method of the 
synthesizing α,α-difluoro-β-amino ketones is possible and should be further explored.  
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1. Introduction 
1.1  Fluorine and Medicinal Chemistry 
Fluorinated organic molecules have practical qualities that are becoming 
increasingly important for drug discovery in the pharmaceutical industry. The Van der 
Waals radius of a fluorine atom is very similar to that a hydrogen atom, so incorporating 
fluorine at sites previously occupied by hydrogen offers minimal steric hindrance.1 This 
similarity makes fluorine a bioisostere of hydrogen.1 As the most electronegative atom, 
fluorine substituents can change the pKa of nearby functional groups, which then 
affects the binding affinity, kinetics, and bioavailability of fluorinated organic 
compounds.1  These characteristics, in turn, can alter the potency, selectivity, and 
toxicity of a drug.1  
In drug design, fluorine is most often utilized for its ability to alter drug metabolism 
and distribution. Drug metabolism refers to the rate at which a compound is broken 
down and eliminated. The bond between carbon and fluorine is extremely stable, with 
a bond energy of 116 kcal/mol, as compared to a carbon-hydrogen bond which is 99 
kcal/mol.2 Therefore, carbon-fluorine bonds cannot be as readily metabolized as 
carbon-hydrogen bonds.2 Furthermore, incorporating fluorine atoms into drugs can 
decrease the metabolic rate by blocking transformations that lead to drug degradation, 
such as oxidation and hydroxylation.2  Overall, enhanced stability and decreased 
metabolism allows extended time for drug uptake, which is important in determining 
bioavailability and dosages. Drug distribution refers to a compound’s ability to reach 
and enter target cells within the body. Some fluorine-containing functional groups can 
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increase drug distribution by enhancing lipophilicity.2 Since the cell membrane is a 
lipid bilayer, increased lipophilicity of a drug yields increased receptor activity and 
drug uptake. This effect is directly related to the number of fluorine substituents. The 
addition of a single fluorine atom confers only a modest improvement in lipophilicity, 
whereas a trifluoromethyl group can dramatically increase lipophilicity.2 
Due to fluorine’s advantageous properties, around 30% of pharmaceuticals are 
fluorinated.3 In the top ten best-selling name brand drugs in 2015, four display at least 
one fluorine atom: Januvia, Advair, Sovaldi, and Crestor.4 The structures of these 
compounds are below shown in Figure 1. Januvia is used for the treatment of type-two 
diabetes.4 This drug works by inhibiting the enzyme that breaks down incretin 
hormones.5 Incretin hormones are the family of hormones that are partially responsible 
for the release of insulin, by limiting their breakdown more insulin is available to 
naturally lower blood sugar.5 Advair is used to treat asthma and chronic obstructive 
pulmonary disease.4 This drug acts as an anti-inflammatory agent that relieves 
constriction of the airways.3 Sovaldi is a medication that blocks the synthesis of viral 
RNA for the treatment of hepatitis C.4,6 Crestor is a statin used to treat high cholesterol.4 
It works by inhibiting HMG-CoA reductase, a key enzyme used in the synthesis of 
cholesterol.3 These four drugs made a combined $19.6 billion in 2015 alone.4  
 3 
 
Figure 1: Examples of fluorinated pharmaceuticals 
1.1.1    Limitations in Drug Design 
Despite the importance of fluorine to the pharmaceutical industry, there are 
many limitations in designing fluorinated drugs. First, fluorine is very rare in 
nature.7 There are only 21 known natural products that contain fluorine and very 
few fluorinating enzymes have been discovered.7 Thus, to integrate fluorine into 
organic compounds, chemists must develop synthetic routes. However, synthetic 
methods of fluorination pose fundamental challenges as well. For example, the 
electronegativity of fluorine limits its reactivity. The electrons around fluorine are 
strongly attracted to its nucleus, and thus unlikely to be donated to form bonds with 
other atoms. Also, fluorine can form hydrogen bonds which makes it a weak 
nucleophile in the presence of hydrogen donors.7 These properties make it difficult 
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to perform nucleophilic substitution reactions that replace hydrogen atoms with 
fluorine.7   
Recently, methods of fluorination have made immense progress. This progress 
is due to the development of new fluorination strategies and an increase in 
commercially available fluorinated intermediates.8 However, much of this progress 
is limited to single or trifluoromethylation. Comparably, there are vastly fewer 
methods for the incorporation of difluoromethyl groups. Because difluoromethyl 
groups are not terminal, newer fluorination strategies such as late-stage fluorination 
cannot be applied;9 therefore, there is a profound interest in discovering new ways 
to incorporate difluoromethyl groups into organic compounds.   
1.2  α,α-Difluoro-β-amino-carbonyl Groups 
One type of difluoromethyl group of particular interest is the α,α-difluoro-β-amino-
carbonyl group. This functional group has been seen in potential drug leads, such as 
those shown in Figure 2. One such drug lead is an analogue of docetaxel. Docetaxel is 
a chemotherapy agent for breast cancer that triggers tumor cell death via microtubule 
disassembly.10 Some 2,2-difluoro analogues of docetaxel proved to be more potent and 
have higher inhibitory activity than docetaxel.10 Furthermore, the 2,2-difluoro 
analogues were twice as active as the monofluorinated 2’-fluorodocetaxel analogue.10 
A similar phenomenon was observed with an analogue of rhodopeptin. Rhodopeptin is 
an antifungal agent.11 Introduction of an α,α-difluoro-β-amino-carbonyl group into 
rhodopeptin showed improved toxicity as compared to the unsubstituted analogue.11  
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Figure 2: Examples of compounds with α,α-difluoro-β-amino-carbonyl groups 
1.2.1    Previous Methods of Synthesis 
The synthesis of compounds containing α,α-difluoro-β-amino-carbonyl groups 
relies on reacting difluoroenolates with imines. These imines can either be activated 
with a protecting group or unactivated and unprotected. The purpose of a protecting 
group is to increase the reactivity of the imine.9 This method is more common but 
it adds both a protection and a deprotection step to the overall synthesis.9 Thus, 
reactions with unactivated imines are more desirable.  There are two established 
methods of reacting an unactivated imine with a difluoroenolate: Reformatsky 
additions12–16 and Mukaiyama additions.17,18 A summary of these two reactions is 
seen below in Figure 3. Both of these reactions are limited in diversity, inefficient, 
and often require harsh conditions. 
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1) Reformatsky Additions 
 
2) Mukaiyama Additions 
 
Figure 3: Existing methods of α,α-difluoro-β-amino-carbonyl synthesis 
In 2011, the Colby laboratory group reported that α,α-difluoroenolates can be 
generated under mild conditions via trifluoroacetate release.19 During this process, 
a base deprotonates a pentafluoro-gem-diol to produce trifluoroacetate and a 
difluoroenolate.19 The difluoroenolate can subsequently react with an aldehyde or 
activated imines, to produce a β-hydroxy- or β-amino- α,α-difluoro ketone, 
respectively.19,20 These reactions are shown in Figure 4.  
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Figure 4: Preparation of α,α-difluoro carbonyl groups from fluorinated gem-diols 
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2. Results and Discussion 
2.1  Mechanism of Trifluoroacetate Release 
My work focuses on using magnesium bases (i.e., Grignard reagents) to react 
difluoroenolates with unactivated imines (Figure 5). The magnesium is potentially able 
to activate the lone pairs on nitrogen and increase the imine’s reactivity. The use of 
unactivated imines is advantageous because it does not require the additional synthetic 
steps associated with using activated imines. If successful, this method has the ability 
to expand the scope of difluoroenolate reactivity with unactivated imines and other 
compounds.  
 
Figure 5: Synthesis of α,α-difluoro-β-amino-carbonyl groups using unactivated 
imines and Grignard reagents 
It was previously reported by the Colby laboratory that a pentafluoro-gem-diol 
could be cleaved into an α,α-difluoroenolate and trifluoroacetate. The highly reactive 
α,α-difluoroenolate is then free to react with other molecules, such as imines (Figure 6, 
Pathway A). However, a major by-product of this reaction forms when the α,α-
difluoroenolate is protonated to form a difluoromethyl ketone; the ketone then reacts 
with an unprotonated enolate to produce the self-adduct (Figure 6, Pathway B). The 
formation of the self-adduct is rapid and irreversible.   
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Figure 6: Mechanism of trifluoroacetate release to form α,α-difluoro-β-amino 
ketones and the self-adduct 
The starting material, a pentafluoro-gem-diol, can be accessed using the 
commercially available trifluoromethyl-1,3-diketone 1. This compound reacts with 
Selectfluor to introduce two fluorine atoms at the a-position, yielding the gem-diol 2. 
The compound exists in the hydrated diol form rather than the diketone form due to the 
high electronegativity of the five surrounding fluorine atoms.  
 
Figure 7: Synthesis of pentafluoro-gem-diol 
2.2 Optimization Studies 
My work began by investigating the formation of α,α-difluoroenolates with 
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studied at different temperatures (rt, 0 °C, and –78 °C) and monitored at different time 
points (5, 10, 15, and 30 min) (Table 1). All of the reactions at rt failed because the 
enolate is unstable at this temperature. At 0 °C, the enolate preferably reacts with a 
protonated enolate (difluoromethyl ketone) to form the self-adduct 3. Reducing the 
temperature to –78 °C limits this side reaction and significantly decreased the formation 
of the self-adduct. The concentration of the protonated enolate 4 was highest after 15 
minutes at –78 °C, at this time there was more than twice as much of the enolate as the 
self-adduct. 
Table 1: Optimization of time in the formation of difluoroenolates  
 
 
Entry Temperature Time (min) Ratio 3:4 
1 rt 5 - 
2 rt 10 - 
3 rt 15 - 
4 rt 30 - 
5 0 °C 5 1 : 0.26 
6 0 °C 10 1: 0.10 
7 0 °C 15 1: 0.28 
8 0 °C 30 1: 0 
9 –78 °C 5 1 : 1.65 
10 –78 °C 10 1 : 1.75 
11 –78 °C 15 1 : 2.17 
12 –78 °C 30 1 : 1.86 
 
After determining the optimal time and temperature, we monitored the effect of 
solvent (Table 2). Trifluoroacetate release is commonly carried out in THF; however, 
we also tried the closely related solvent, ether, as well as a 1:1 mixture of both. The 
reaction in THF gave the highest concentration of the protonated difluoroenolate 4.  
CF3
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F F
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Table 2: Optimization of solvent in the formation of difluoroenolates 
 
 
Entry Solvent Ratio 3:4 
1 THF 1 : 2.17 
2 ether 1 : 1.06 
3 THF/ether (1:1) 1 : 1.76 
 
Next, various magnesium bases were tested to determine if the steric hindrance of 
certain bases limited product formation (Table 3). The results for EtMgBr, n-BuMgCl, 
and PhMgBr were comparable to that of i-PrMgCl (Table 2, Entry 1). The reaction with 
i-PrMgCl•LiCl showed a significant decrease in difluoroenolate formation. It was 
concluded that using i-PrMgCl was sufficient for further studies.  
Table 3: Optimization of base in the formation of difluoroenolates 
 
 
Entry Base Ratio A:B 
1 EtMgBr 1 : 2.29 
2 n-BuMgCl 1 : 2.22 
3 PhMgBr 1 : 2.08 
4 i-PrMgCl•LiCl 1 : 1.65 
 
2.3  Synthesis of α,α-Difluoro-β-amino Ketones 
Once the optimized conditions were determined, they were applied to the synthesis 
of α,α-difluoro-β-amino ketones. After 15 minutes of stirring, an imine (N-
benzylidenebenzylamine, 5) was added to initiate formation of the product 6. The 
results of these reactions at various temperatures are listed in Table 4.  Initially, the 
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reaction was run at the temperature optimized for formation of the enolate (–78 °C). 
After 2 hours, only trace amounts of the product were observed. Next, we increased the 
temperature to 0 °C and rt, in order to facilitate an increase in the product formation. 
These reactions gave a mixture of by-products, including both the self-adduct and 
protonated difluoroenolate. Despite being able to protonate and identify the enolate 
after trifluoroacetate release, we were unable to react it with a subsequent imine to 
produce the desired product. 
Table 4: Optimization of temperature in α,α-difluoro-β-amino ketone synthesis 
 
 
Entry Temperature Product 
1 –78 °C 2, 3, 4 
2 0°C 3, 4 
3 rt 3, 4 
 
2. 4  Alternate Method of Synthesis 
In the previously discussed method of α,α-difluoro-β-amino ketone synthesis, the 
difluoroenolate was pre-formed before the imine was added. During its formation, 
almost one third of the enolate was converted into self-adduct. Also, the enolate 
intermediate is unstable and did not react effectively with the imine. We next designed 
an alternate method that reduced self-adduct formation and did not require stabilization 
of the enolate intermediate. In this method, the starting material, LiBr, and an imine 
were combined in solvent before adding the base. By rearranging the order, the base is 
able to immediately react with the diol and initiate difluoroenolate formation which can 
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subsequently react with the already present imine. In this method, the enolate can react 
immediately with imine instead of being protonated and forming the adduct.  
The conditions for this procedure were adapted from similar aldehyde reactions 
reported in the literature.19 To a solution of pentafluoro-gem-diol and LiBr, the imine 
was added, followed by i-PrMgCl at rt. After 30 minutes of stirring, this reaction 
produced the product 6 in a 67% yield. (Figure 8). The reaction was also performed 
without the LiBr, but gave inferior results. These results proved that the LiBr additive 
is necessary to increase the reactivity of i-PrMgCl.21  
 
 
Figure 8: Synthesis of α,α-difluoro-β-amino ketones with an alternative method 
 
Next, the scope of reactivity with various unactivated imines was investigated 
(Table 5). The phenyl and benzyl substituted imines were replaced with imines 
containing electron-donating, electron-withdrawing, and alkyl substituents. The 
highest yield was seen with imine 5 that had both a phenyl and a benzyl substituent 
which gave a yield of 67%. Replacing the benzyl with a t-butyl group (Table 5, entry 
2) gave a yield of 50%. The presence of two electron-donating methoxy groups on 
imine 9 slightly decreased the yield to 44% (Table 5, entry 3). The electron-
withdrawing fluorophenyl group on imine 11 significantly decreased the yield to 14% 
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(Table 5, entry 4). In the case of imine 13, two phenyl groups at each substituent gave 
the lowest yield of 7% (Table 5, entry 5).  
Table 5: Grignard-promoted imine addition studies 
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2.5  Identification and Analysis 
       The primary method used to identify synthesized compounds was nuclear 
magnetic resonance spectroscopy (NMR). Specifically, fluorine NMR (19F-NMR) 
helped verify the presence and number of fluorine atoms in each compound. The 
starting material, self-adduct, difluoroenolate, and α,α-difluoro-β-amino ketones all 
gave unique peaks on the 19F-NMR spectrum. Differentiating between these peaks 
provided information about the success and product yield of each reaction. The product 
yield was determined by integrating the product peak and comparing it to the 
integration of a standard, trifluorotoluene.  
During the optimization studies, the amount of difluoroenolate produced during 
the reaction was also quantified by 19F-NMR. Each reaction was quenched with D2O 
producing a deuterated difluoroenolate. The deuterated enolate produced a triplet F-
NMR peak that was unique from the doublet produced by the hydrogen protonated 
enolate. The formation of each enolate is shown in Figure 9. This allowed us to 
determine exactly how much of the enolate was formed during the time course of the 
reaction, which was necessary during time optimization studies. 
 
Figure 9: Protonation and deuteration of difluoroenolates  
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3. Conclusion 
In summary, two methods were tested for synthesizing α,α-difluoro-β-amino 
ketones. The first method involved preforming the difluoroenolate intermediate before 
imine addition. After extensive optimization, it was decided that this method could not 
produce the desired product in good yield. An alternate method was developed where the 
imine was present to react immediately as the enolate formed. This method also helped 
avoid the formation of the self-adduct – a major by-product of the first method. The 
results were significantly better and allowed for the synthesis of various compounds with 
the α,α-difluoro-β-amino-carbonyl group. The optimal yield was 67%. The new synthetic 
method provides an extension of the known reactivity of difluoroenolates produced from 
pentafluoro-gem-diols with a Grignard base. It adds a new strategy to produce valuable 
α,α-difluoro-β-amino-carbonyl groups.    
 17 
4. Experimental Details 
All reactions were completed under argon. 
 
2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalene-2-yl)-butan-1-one 2. A solution of 
4,4,4-trifluoro-3-hydroxy-1-(naphthalen-2-yl)but-2-en-1-one 1 (500.00 mg, 1.88 mmol) in 
CH3CN (7.0 mL) was treated with Selectfluorâ (1.66 g, 4.70 mmol) at rt. After 24 h, the 
reaction was diluted in EtOAc (40 mL) and filtered with Celite. The residue was 
concentrated in vacuo, dissolved in CH2Cl2 (40 mL) and washed with water (40 mL). The 
aqueous layer was extracted with CH2Cl2 (40 mL). The combined organics were dried over 
Na2SO4 and concentrated under reduced pressure to give the final product 2 as a yellow 
solid in a 95% yield (573 mg): 19F NMR (376 MHz, CDCl3) δ –81.0 (t, J = 11.2 Hz, 3F), –
111.2 (q, J = 11.1 Hz, 2F). 
 
Representative Reaction for Trifluoroacetate release from 2,2,4,4,4-pentafluoro-3,3-
dihydroxy-1-(naphthalen-2-yl)-butan-1-one 2. To a solution of LiBr (20.0 mg, 0.23 
mmol) in THF (1 mL) was added i-PrMgCl (115 µL, 0.230 mmol) at –78 °C. Then 
2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalene-2-yl)-butan-1-one 2 (25 mg, 0.080 
mmol) was added dropwise. After 15 min, the reaction was quenched with D2O  (1 mL). 
The organics were extracted with CH2Cl2 (5 mL ´ 3),  dried over Na2SO4, and 
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concentrated under reduced pressure: 19F NMR (376 MHz, CDCl3) δ –102.3––109.1 (m, 
2F)a, –121.2 (d, J = 53.5 Hz, 2F)b, –121.9 (t, J = 8.1 Hz, 2F)c, –128.3––131.4 (m, 2F)a. [a 
denotes self-adduct, b denotes protonated enolate, c denotes deuterated enolate] 
 
3-(benzylamino)-2,2-difluoro-1-(naphthalen-2-yl)-3-phenylpropan-1-one 6. To a 
solution of LiBr (20.0 mg, 0.23 mmol) in THF (1 mL) was added i-PrMgCl (0.12 mL, 0.23 
mmol) at –78 °C. Then 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalene-2-yl)-butan-
1-one 2 (25 mg, 0.080 mmol) was added dropwise. After 15 min, N-
benzylidinebenzylamine 5 (30.0 µL, 0.16 mmol) was added and the reaction was warmed 
to 0 °C. After 2 h, the reaction was quenched with D2O (1 mL). The organics were extracted 
with CH2Cl2 (5 mL ´ 3), dried over Na2SO4, and concentrated under reduced pressure: 19F 
NMR (471 MHz, CDCl3) δ –101.7 (dd, J = 268.5, 7.5 Hz, 1F), –114.1 (dd, J = 268.5, 20.1 
Hz, 1F).  
 
3-(benzylamino)-2,2-difluoro-1-(naphthalen-2-yl)-3-phenylpropan-1-one 6. To a 
solution of LiBr (41 mg, 0.47 mmol) and 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-
(naphthalene-2-yl)-butan-1-one 2 (50.0 mg, 0.16 mmol) in THF (1.6 mL) was added N-
benzylidinebenzylamine 5 (60.0 µL, 0.31 mmol) at rt. Then, i-PrMgCl was added dropwise 
(0.24 mL, 0.47 mmol). After 30 min, the reaction was quenched with NH4Cl (3.0 mL): 19F 
CF3
O OHHO
F F
N
PhH
Ph
Ph
O
F F
HN Phi-PrMgCl, LiBr
THF, –78 ºC, 2 h
2 65
+
i-PrMgCl, LiBr
THF, rt, 30 min
CF3
O OHHO
F F
N
PhH
Ph
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O
F F
HN Ph
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+
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NMR (376 MHz, CDCl3) δ –101.6 (dd, J = 266.4, 7.0 Hz, 1F), –115.9 (dd, J = 266.4, 21.2 
Hz, 1F). 
 
3-(benzylamino)-2,2-difluoro-1-(naphthalen-2-yl)-3-phenylpropan-1-one 6. To a 
solution of 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-(naphthalene-2-yl)-butan-1-one 2 (50.0 
mg, 0.16 mmol) in THF (1.6 mL) was added N-benzylidinebenzylamine 5 (60.0 µL, 0.31 
mmol) at rt. Then, i-PrMgCl was added dropwise (0.24 mL, 0.47 mmol). After 30 min, the 
reaction was quenched with NH4Cl (3.0 mL): 19F NMR (376 MHz, CDCl3) δ –101.7 (dd, 
J = 266.3, 7.3 Hz, 1F), –115.5 (dd, J = 267.0, 21.7 Hz, 1F). 
 
3-(tert-butylamino)-2,2-difluoro-1-(naphthalen-2-yl)-3-phenylpropan-1-one 10. To a 
solution of LiBr (41 mg, 0.47 mmol) and 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-
(naphthalene-2-yl)-butan-1-one 2 (50.0 mg, 0.16 mmol) in THF (1.6 mL) was added N-
benzylidene-tert-butylamine 7 (55 µL, 0.31 mmol) at rt. Then, i-PrMgCl was added 
dropwise (0.24 mL, 0.47 mmol). After 30 min, the reaction was quenched with NH4Cl (3.0 
mL): 19F NMR (376 MHz, CDCl3) δ  –99.6 (dd, J = 258.3, 5.7 Hz, 1F), –118.1 (dd, J = 
257.8, 23.2 Hz, 1F). 
 
i-PrMgCl
THF, rt, 30 min
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2,2-difluoro-3-(4-methoxyphenyl)-3-((4-methoxyphenyl)amino)-1-(naphthalen-2-
yl)propan-1-one 8. To a solution of LiBr (41 mg, 0.47 mmol) and 2,2,4,4,4-pentafluoro-
3,3-dihydroxy-1-(naphthalene-2-yl)-butan-1-one 2 (50.0 mg, 0.16 mmol) in THF (1.6 mL) 
was added N-(4-methoxybenzylidene)-4-methoxyaniline 9 (75 mg, 0.31 mmol) at rt. Then, 
i-PrMgCl was added dropwise (0.24 mL, 0.47 mmol). After 30 min, the reaction was 
quenched with NH4Cl (3.0 mL): 19F NMR (376 MHz, CDCl3) δ –102.1 (dd, J = 267.3, 7.7 
Hz, 1F), –114.8 (dd, J = 267.3, 19.8 Hz, 1F). 
 
3-((3,4-dimethylphenyl)amino)-2,2-difluoro-3-(4-fluorophenyl)-1-(naphthalen-2-
yl)propan-1-one 12. To a solution of LiBr (41 mg, 0.47 mmol) and 2,2,4,4,4-pentafluoro-
3,3-dihydroxy-1-(naphthalene-2-yl)-butan-1-one 2 (50.0 mg, 0.16 mmol) in THF (1.6 mL) 
was added 3,4-dimethyl-N-(4-fluorobenzylidene)aniline 11 (70.0 mg, 0.31 mmol) at rt. 
Then, i-PrMgCl was added dropwise (0.24 mL, 0.47 mmol). After 30 min, the reaction was 
quenched with NH4Cl (3.0 mL): 19F NMR (376 MHz, CDCl3) δ –101.6 (dd, J = 270.6, 7.3 
Hz, 1F), –114.4 (dd, J = 270.8, 20.0 Hz, 1F). 
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2,2-difluoro-1-(naphthalen-2-yl)-3-phenyl-3-(phenylamino)propan-1-one 14. To a 
solution of LiBr (41 mg, 0.47 mmol) and 2,2,4,4,4-pentafluoro-3,3-dihydroxy-1-
(naphthalene-2-yl)-butan-1-one 2 (50.0 mg, 0.16 mmol) in THF (1.6 mL) was added N-
benzylideneaniline 13 (56 mg, 0.31 mmol) at rt. Then, i-PrMgCl was added dropwise (0.24 
mL, 0.47 mmol). After 30 min, the reaction was quenched with NH4Cl (3.0 mL): 19F NMR 
(376 MHz, CDCl3) δ –102.2 (dd, J = 269.9, 6.7 Hz), –113.7 (dd, J = 253.2, 20.6 Hz). 
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